Human Oncology & Pathogenesis Program
The Sarat Chandarlapaty Lab
Research
My lab focuses on understanding the regulation of growth factor signal transduction pathways that are aberrantly activated in cancers, with a focus on those implicated in breast cancer pathogenesis.
Publications Highlights
Will M, Liang J, Metcalfe C, Chandarlapaty S. Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat Rev Cancer. 2023 Oct;23(10):673-685. doi: 10.1038/s41568-023-00604-3. Epub 2023 Jul 27. Review. PubMed PMID: 37500767; PubMed Central PMCID: PMC10529099.
Li Q, Jiang B, Guo J, Shao H, Del Priore IS, Chang Q, Kudo R, Li Z, Razavi P, Liu B, Boghossian AS, Rees MG, Ronan MM, Roth JA, Donovan KA, Palafox M, Reis-Filho JS, de Stanchina E, Fischer ES, Rosen N, Serra V, Koff A, Chodera JD, Gray NS, Chandarlapaty S. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer Discov. 2022 Feb;12(2):356-371. doi: 10.1158/2159-8290.CD-20-1726. Epub 2021 Sep 20. PubMed PMID: 34544752; PubMed Central PMCID: PMC8831444.
Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020 Apr;1(4):382-393. doi: 10.1038/s43018-020-0047-1. Epub 2020 Mar 23. PubMed PMID: 32864625; PubMed Central PMCID: PMC7450824.
Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006. PubMed PMID: 30537512; PubMed Central PMCID: PMC6294301.
Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3. PubMed PMID: 24185512; PubMed Central PMCID: PMC3903423.
People
Sarat Chandarlapaty, MD, PhD
Naddisy Foundation Chair in Breast Cancer Research
- Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.
- MD, Wake Forest School of Medicine
- PhD, University of North Carolina
- [email protected]
- Email Address
- View physician profile
- Physician profile
Members
Lab Alumni
Lab Affiliations
Achievements
Clinical Investigator Award, Damon Runyon Cancer Research Foundation (2012)
Young Investigator Award, American Society of Clinical Oncology (2007)
Fellow in Biomedical Research, The Dana Foundation (2006)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Career Opportunities
Get in Touch
-
Lab Head Email
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Sarat Chandarlapaty discloses the following relationships and financial interests:
-
AstraZeneca
Professional Services and Activities -
Blueprint Medicines
Professional Services and Activities -
Casdin Capital, LLC
Professional Services and Activities -
Daiichi Sankyo
Professional Services and Activities -
eFFECTOR Therapeutics
Equity; Professional Services and Activities -
Eli Lilly and Company
Professional Services and Activities (Uncompensated) -
Encore Medical Education
Professional Services and Activities -
Genesis Therapeutics
Professional Services and Activities
-
Gerson Lehrman Group
Professional Services and Activities -
Novartis
Professional Services and Activities -
Nuvalent, Inc.
Professional Services and Activities -
Odyssey Biosciences
Equity; Fiduciary Role / Position; Intellectual Property Rights -
Prelude Therapeutics
Professional Services and Activities -
SAGA Diagnostics
Professional Services and Activities -
Springer Nature Limited
Professional Services and Activities -
Totus Medicines Inc.
Equity
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].